Sales and Marketing Best Practices
Best Practices, LLC has conducted extensive research in the field of Sales and Marketing. Browse through and sample our published Sales and Marketing research in the topics below:
| |  | Ensuring Brand & Health Safety from Parallel Importation and Counterfeits  
Study Overview
This 66-slide presentation examines how companies organize Brand Security functions to safeguard against unauthorized parallel imports and counterfeit products across business units and geographies. Pharmaceutical, biotech and manufacturing companies can benefit from this presentation as it details operational tactics to safeguard brands, as well as potential pitfalls to those tactics.
Key Topics
Key Findings
Operational Tactics to Safeguard brands
Structure, Staff and Resource Investment in the Brand Security Function
Brand Security Processes and Procedures
Top Lessons Learned
Key Findings
The supply chain rates as an area of key concern for most pharmaceutical companies. Those companies that can deal with potential problems at the supply chain level are better positioned to control brand security.
Tamper-evident packaging is seen as one of the best manufacturing approaches to safeguard pharmaceutical products as 91% find it to be an effective tactic. Ongoing expense and regulatory concerns were the most frequently cited implementation elements to be managed for this tactic.
Below are two examples of safeguards that proved to be useful to many companies:
Trademark Safeguards: Trademark and name differentiation are the highest rated safeguards on this brand security front.
Regulatory Safeguards: Proper labeling showing that the drug adheres to manufacturing standards is the preferred regulatory safeguard.
Methodology
This document is the result of a Best Practices, LLC project for a pharmaceutical Business Excellence Board client. It is based on the survey responses of 11 leading benchmark partners in the pharmaceutical, biotech and manufacturing industries.
Medical Science Liaison Services Excellence: Exploring Future Services for Diverse Customer Groups
Non-members: Click here to review a complimentary excerpt from " Medical Science Liaison Services Excellence: Exploring Future Services for Diverse Customer Groups
STUDY OVERVIEW
Charged with being the chief connection between a company's science and critical stakeholders in the marketplace, Medical Science Liaisons (MSLs) are attracting more attention from pharmaceutical executives. However, both their policy direction and manner in which MSLs interface with key stakeholders are evolving.
Best Practices, LLC conducted this study to investigate the changing role of MSLs in serving their key constituents. This research presents benchmarks around key MSL services within payer education and support, hospital/ health care access, physician education and patient education. Biopharmaceutical and medical device executives can use this study to assess resource allocation of MSLs and key strategies used in MSL interfacing as it evolves in the future.
Note: Data are presented in two segments: The total benchmark class and a U.S. only segment.
KEY TOPICS
Relations of Payer Affairs with MSLs
Future High Value Activities for MSLs
Evolving Policies and Procedures for MSL activities
Role of MSLs in Serving Medical Systems
SAMPLE KEY METRICS
Structures that work best to provide MSL services in coordination with Payer Affairs
Internal groups emerging as valuable users of MSL support or services in the next 12-24 months
Policy directions for different activities in the next 24 months
Types of healthcare systems that may increasingly be homes to KOLs
FTE resources spent on Internal and External Quality Audit Activities
Services new or specialized educators provide to customers
How MSLs interface with Professional Organizations
MSLs' support of internal customers
SAMPLE KEY FINDING
Recognize Payers Groups Are Growing in Importance: Sixty percent of respondents believe that managed care groups will be valuable users of MSL support services in the next two years. MSLs will need to understand how payer groups work and how best to serve internal constituents working with them. At present only about 30% of companies regularly support internal payer groups.
Limited Fear of Losing Access to KOLs: A little more than one-third of companies say the see a high risk of KOL’s home institutions curtailing MSL access to such opinion leaders. Some did point out that some MSLs are becoming “too commercial” in their touch points and that could negatively impact access if it continues.
METHODOLOGY
Thirty-five research Pharmaceutical and Medical Device executives from 30 companies participated in this project. The benchmark class, of global pharmaceutical and medical device companies, has been segmented into two classes based on geographic coverage (Total Benchmark and U.S. focus).
Top 5 Best Practices in Launching Blockbuster Drugs
This document contains five top practices in launching blockbuster drugs. The leading practices, managerial insights and benchmark metrics in this report are drawn from in-depth interviews with more than 24 executives at 12 leading pharmaceutical companies.
“Top Five Best Practices in Launching Blockbuster Drugs” includes a top practice from each of five functional areas identified through extensive research and interviews.
|
|